Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The Prognostic Nutritional Index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L).

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Francesco Caputo

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

F. Caputo1, M. Salati2, K. Cerma3, A. Spallanzani4, K. Andrikou5, F. Gelsomino1, G. Orsi1, G. Rovesti6, M.L. Riggi3, E. Molinaro7, C. Santini8, C. Bardasi4, M. Rimini9, S. Pipitone8, G. Cortesi1, F.M. Schipilliti1, F. Canino3, A. Casadei-gardini2, S. Cascinu1

Author affiliations

  • 1 Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 2 Medical Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 3 Oncology, Azienda Ospedaliera - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 4 Oncologia, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 5 Modena, Azienda Ospedaliera - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 6 Oncology And Hematology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 7 Dipartimento Di Oncologia Ed Ematologia, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 8 Oncologia Medica, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 9 Department Of Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
More

Resources

Abstract 2733

Background

ABC portend a dismal prognosis despite standard chemotherapy treatment. A proper risk-stratification is key to optimize the benefit-to-risk ratio of palliative treatment. The PNI is an immune-inflammatory and nutritional indicator showing to be prognostic across a number of malignancies. We aimed at investigating the impact on survival of the PNI in ABC patients (pts) treated with 1L.

Methods

Electronic medical records of pts diagnosed with ABC and treated with 1L between 2002 and 2018 at the Modena Cancer Centre were retrospectively reviewed. Clinical, pathological and biochemical variables of potential interest were collected. The PNI was calculated as follows: 10 × serum albumin concentration (g/dL) + 0.005 × peripheral lymphocyte count (number/mm2) and dichotomized using the ROC analysis with 36.7 as the cut-off value. Univariate and multivariate analysis were performed to assess the impact of covariates on overall survival (OS). Kaplan-Meier survival curves were generated and log-rank testing was used to make comparisons.

Results

Overall, 114 pts fulfilled the inclusion criteria and were included in the analysis. 51% (n = 58) were female and 49% (n = 56) had an ECOG PS of 0. 35% (n = 40) of pts received a platinum/gemcitabine doublet, while 65% (n = 74) were treated with other regimens. The median OS in the cohort was 8.1 months. At the univariate analysis the following covariates were associated with OS: PNI (P < 0.0001), CA19.9 (P = 0.0063), CEA (P = 0.0004), LDH (P = 0.0360), alkaline phosphatase (P = 0.0308), monocyte count (P = 0.0124), neutrophil count (P = 0.0013), ECOG PS (P < 0.0001), neutrophil/lymphocyte ratio (NLR) (P < 0.0001). Interestingly, the PNI retained a statistical significance (P = 0.0011) also at the multivariate analysis, together with NLR (P = 0.0046) and ECOG PS (<0.0001). The median OS in pts with a PNI > 36.7 and < 36.7 was 12.1 months and 5.4 months, respectively.

Conclusions

We demonstrated an independent prognostic role for the PNI in a cohort of ABC treated with 1L. Since it is based on easy-to-collect and inexpensive parameters it should be implemented in the clinical practice to improve the accuracy of current available tools.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Francesco Caputo.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings